In phase II LipCap, liposomal irinotecan plus capecitabine with long-course chemoradiotherapy produced a 21.7% overall complete response rate in LARC, with grade 3-4 toxicity in 16.7%. Long-term efficacy remains unknown.
In randomized TORCH-iTNT, adding 25 Gy in 5 fractions before CAPOX plus toripalimab increased complete response from 37.1% to 61.5% in pMMR locally advanced rectal cancer. Long-term outcomes remain pending.
In a randomized phase III trial, short-course RT-based TNT produced a numerically higher pCR rate than long-course chemoradiotherapy, but no significant DFS, LRFS, or OS benefit emerged after 28 months of follow-up.
In randomized TORCH-PM01, adding FAPI-guided hypofractionated RT and cadonilimab to second-line systemic therapy increased objective response from 15% to 60% and conversion to cytoreductive surgery from 20% to 60%.
In randomized STELLAR II, adding sintilimab to short-course RT-based TNT increased complete response from 26.8% to 51.9% in pMMR locally advanced rectal cancer, with higher toxicity. Three-year DFS remains pending.
Nearly three in ten surveyed cervical cancer survivors reported partial-to-probable PTSD symptoms several years after HDR brachytherapy.
Sequential chemotherapy plus five-fraction SBRT produced 86.7% one-year local control with 7.7% acute grade 3 toxicity in STARLORD.
A five-point framework standardized knee osteoarthritis LDRT plan assessment, with high agreement among four radiation oncologists.
Standardized joint contours showed that higher D50% and mean joint dose were associated with grade ≥2 stiffness after extremity sarcoma RT.
Faster PSA rise after testosterone recovery tracked progression, but associations with distant metastasis were inconsistent and too imprecise for clinical inference.
In randomized phase III PACE-A, 5-fraction SBRT and radical prostatectomy both achieved excellent long-term disease control in localized prostate cancer, with no significant efficacy difference after a median 8 years of follow-up.
In phase III NRG-CC009, SRS did not improve neurocognitive failure vs HA-WBRT plus memantine, but median OS was 17.4 vs 8.6 months. Adjusted intracranial control, neurologic mortality, and grade 3-5 toxicity were similar.
In phase III Alliance A071801, postoperative fractionated SRS improved 1-year surgical bed control to 87% vs 81% with single-fraction SRS, without significantly increasing radiation necrosis. Overall survival also favored fSRS.
In randomized phase III NRG-GI003, protons substantially reduced non-tumor liver dose but did not improve OS, PFS, or local progression over photons in advanced HCC. Grade 3+ toxicity was numerically lower.
Ten-year CHN HYPOPMRT results show durable locoregional control and similar survival with 43.5 Gy in 15 fractions vs 50 Gy in 25 fractions after mastectomy, with no emerging severe late-toxicity signal.